The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue 5, 2012, Pages 410-419

  Svendsen, Pernille F ^a   Jensen, Frank K ^c   Holst, Jens J ^d   Haugaard, Steen B ^b   Nilas, Lisbeth ^a   Madsbad, Sten ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Department of Endocrinology ^*  (Denmark)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Body fat distribution; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Insulin resistance; Obesity; Polycystic ovary syndrome; Testosterone; Weight loss

Indexed keywords

ANDROGEN; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CALORIMETRY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; LOW CALORY DIET; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WEIGHT REDUCTION; X RAY SPECTROMETRY;

ADULT; ANDROGENS; BODY COMPOSITION; BODY WEIGHT; CALORIC RESTRICTION; DIHYDROTESTOSTERONE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTRA-ABDOMINAL FAT; LIPID MOBILIZATION; OBESITY; TESTOSTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865324947     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2012.691542     Document Type: Article

References (66)

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
2. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165-71.
3. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale effi cacy trials. Obesity (Silver Spring) 2009; 17:S43-8.
4. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. Very low-calorie diets. JAMA 1993;25(270):967-74.
5. Murphy EJ. Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism. J Anim Sci 2006;84:94-104.
6. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006;22:2917-21. (Pubitemid 43729162)
7. Bousquet-Melou A, Galitzky J, Lafontan M, Berlan M. Control of lipolysis in intra-abdominal fat cells of nonhuman primates: comparison with humans. J Lipid Res 1995;36:451-61.
8. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006;95:136-47.
9. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002;18:5-9.
10. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar Hen A, Bedossa P, Guerre-Millo M, Cl ément K. Increased infi ltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006;55: 1554-61. (Pubitemid 44324107)
11. Mcintyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1.
12. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297:127-36.
13. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52. (Pubitemid 16162741)
14. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13. (Pubitemid 32195226)
15. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplifi cation of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45: 1111-9. (Pubitemid 34985287)
16. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006;91:1916-23.
17. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9. (Pubitemid 32848563)
18. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25:1206-14. (Pubitemid 32721544)
19. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellström PM. Prandial subcutaneous injections of glucagon- like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004;91:439-46. (Pubitemid 38386908)
20. Holst JJ. Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ 2010;50:121-35.
21. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983;55:628-34. (Pubitemid 13044099)
22. Gotfredsen A, Baeksgaard L, Hilsted J. Body composition analysis by DEXA by using dynamically changing samarium fi ltration. Appl Physiol 1997;82:1200-9. (Pubitemid 27172322)
23. Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas 1980 ;2:109-18. (Pubitemid 11198345)
24. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72. (Pubitemid 30645223)
25. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycineextended glucagon-like peptide I in humans. Diabetes 1994;43:535-9. (Pubitemid 24096293)
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-9. (Pubitemid 15018832)
27. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-64. (Pubitemid 26308809)
28. Tai JF. Review: the use of isotopic steroidsfor the measurement of production rates in vivo. J Clin Endocrinol Metab 1963;23:1285-97.
29. Rabol R, Svendsen PF, Skovbro M, Boushel R, Haugaard SB, Schjerling P, Schrauwen P, Hesselink MK, Nilas L, Madsbad S, Dela F. Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss. Metabolism 2009;58: 1145-52.
30. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: fi ndings from a systematic review. Int J Obes (Lond) 2008;32:619-28. (Pubitemid 351536009)
31. Jensen MD. Health consequences of fat distribution. Horm Res 1997;48:88-92.
32. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP, Lamarche B. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002;160:377-84. (Pubitemid 34159331)
33. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2001;280: E1000-6.
34. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976;12:563-71.
35. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47. (Pubitemid 14229053)
36. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993;92:91-8. (Pubitemid 23208984)
37. Hennes MM, Shrago E, Kissebah AH. Mechanism of free fatty acid effects on hepatocyte insulin receptor binding and processing. Obes Res 1993;1:18-28.
38. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230-9. (Pubitemid 27386309)
39. Jensen MD. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 2006;14:20S-4S.
40. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-8. (Pubitemid 40322060)
41. Turner RC, Holman RR. Insulin rather than glucose homoeostasis in the pathophysiology of diabetes. Lancet 1976;1:1272-4.
42. Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23. (Pubitemid 9249478)
43. Defronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009;32:S157-63.
44. Brons C, Vaag A. Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes. J Physiol 2009;587:3977-8.
45. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.
46. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ. Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring) 2009;17: 1070-6.
47. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction 2010;140:347-64.
48. Zain MM, Norman RJ. Impact of obesity on female fertility and fertility treatment. Womens Health (Lond Engl) 2008;4:183-94. (Pubitemid 351513638)
49. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007;14:482-7. (Pubitemid 350059360)
50. ESHRE Capri Workshop Group. Nutrition and reproduction in women. Hum Reprod Update 2006;12:193-207.
51. Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 2000;24: S56-8. (Pubitemid 30461949)
52. Tchernof A, Labrie F, Belanger A, Despres JP. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol 1996;150: S155-64.
53. Maclaren NK, Gujral S, Ten S, Motagheti R. Childhood obesity and insulin resistance. Cell Biochem Biophys 2007;48:73-8. (Pubitemid 47340873)
54. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004;89:2526-39. (Pubitemid 38766328)
55. Saenger P, Dimartino-Nardi J. Premature adrenarche. J Endocrinol Invest 2001;24:724-33. (Pubitemid 32982342)
56. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36: 105-11.
57. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:1928-32. (Pubitemid 37107570)
58. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-9. (Pubitemid 36207827)
59. Moran LJ, Brinkworth GD, Norman RJ. Dietary therapy in polycystic ovary syndrome. Semin Reprod Med 2008;26: 85-92.
60. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;81:630-7. (Pubitemid 38376121)
61. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck- Nielsen H. Diurnal profi le of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 1983;7:529-38. (Pubitemid 14239953)
62. Naslund E, Gryback P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, Hellström PM. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998;43:945-52. (Pubitemid 28211450)
63. Jones IR, Owens DR, Luzio SD, Hayes TM. Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabete Metab 1989;15:11-22. (Pubitemid 19091052)
64. de Luis DA, Gonzalez SM, Conde R, Aller R, Izaola O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab 2007;51: 134-8. (Pubitemid 46975991)
65. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009;35:513-7.
66. Adam TC, Lejeune MP, Westerterp-Plantenga MS. Nutrient- stimulated glucagon-like peptide 1 release after bodyweight loss and weight maintenance in human subjects. Br J Nutr 2006;95:160-7. (Pubitemid 43250723)